The first EGFR-targeting TKI, gefitinib, was approved in 2003 for non-small cell lung cancer (NSCLC), followed by erlotinib for NSCLC and pancreatic cancer in 2004 and 2005, respectively [38,39,40]. This evidence concerns the gene EGFR and familial pancreatic carcinoma.